Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
Colorcon
Dow
AstraZeneca

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022417

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 022417 describes NORVIR, which is a drug marketed by Abbott, Abbvie, and Abbvie Inc, and is included in five NDAs. It is available from four suppliers. There are eight patents protecting this drug and two Paragraph IV challenges. Additional details are available on the NORVIR profile page.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ritonavir profile page.
Summary for 022417
Tradename:NORVIR
Applicant:Abbvie
Ingredient:ritonavir
Patents:6
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022417
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NORVIR ritonavir TABLET;ORAL 022417 NDA AbbVie Inc. 0074-3333 0074-3333-30 30 TABLET, FILM COATED in 1 BOTTLE (0074-3333-30)
NORVIR ritonavir TABLET;ORAL 022417 NDA A-S Medication Solutions 50090-1162 50090-1162-0 30 TABLET, FILM COATED in 1 BOTTLE (50090-1162-0)
Paragraph IV (Patent) Challenges for 022417
Tradename Dosage Ingredient NDA Submissiondate
NORVIR TABLET;ORAL ritonavir 022417

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:Feb 10, 2010TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Jan 19, 2020Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:May 10, 2021Product Flag?Substance Flag?Delist Request?Y
Patent:  Start TrialPatent Expiration:Feb 25, 2025Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 022417

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010   Start Trial   Start Trial
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010   Start Trial   Start Trial
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010   Start Trial   Start Trial
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
AstraZeneca
McKesson
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.